Titan Pharmaceut Financials

TTNP

Source SEC Filings (10-K/10-Q) Updated Jun 30, 2025 Currency USD FYE December

This page shows Titan Pharmaceut (TTNP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Titan Pharmaceut passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.82x

For every $1 of reported earnings, Titan Pharmaceut generates $0.82 in operating cash flow (-$3.9M OCF vs -$4.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

-$4.6M

YoY+36.5%

Titan Pharmaceut's EBITDA was -$4.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 36.5% from the prior year.

Free Cash Flow

N/A

Net Income

-$4.7M

YoY+15.5%

Titan Pharmaceut reported -$4.7M in net income in fiscal year 2024. This represents an increase of 15.5% from the prior year.

EPS (Diluted)

$-5.23

YoY+29.4%

Titan Pharmaceut earned $-5.23 per diluted share (EPS) in fiscal year 2024. This represents an increase of 29.4% from the prior year.

Cash & Debt

$2.8M

YoY-58.1%

5Y CAGR-11.5%

10Y CAGR-15.6%

Titan Pharmaceut held $2.8M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

914,234

YoY+17.0%

Titan Pharmaceut had 914,234 shares outstanding in fiscal year 2024. This represents an increase of 17.0% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

TTNP Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	$184K-67.0%	$557K-63.5%	$1.5M-68.5%	$4.8M+85.7%	$2.6M
Cost of Revenue	N/A	N/A	N/A	$199K-57.8%	$472K	$0
Gross Profit	N/A	N/A	N/A	$1.3M-69.6%	$4.4M+67.6%	$2.6M
R&D Expenses	N/A	$1.9M-59.8%	$4.8M-16.4%	$5.7M-3.8%	$5.9M+16.5%	$5.1M
SG&A Expenses	$4.6M-17.9%	$5.5M-8.1%	$6.0M+20.9%	$5.0M-14.0%	$5.8M-51.4%	$11.9M
Operating Income	-$4.6M+37.4%	-$7.3M+28.9%	-$10.2M-9.4%	-$9.4M-27.2%	-$7.4M+6.7%	-$7.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$1K0.0%	$1K+125.0%	-$4K	$0	$0	$0
Net Income	-$4.7M+15.5%	-$5.6M+45.4%	-$10.2M-16.3%	-$8.8M+51.9%	-$18.2M-10.8%	-$16.5M
EPS (Diluted)	$-5.23+29.4%	$-7.41+51.2%	$-15.19	$-0.90+54.1%	$-1.96	$-0.72

Metric	Q2'25	Q1'25	Q2'24	Q3'24	Q1'24	Q4'23	Q3'23	Q2'23
Revenue	N/A	N/A	N/A	N/A	N/A	-$1K-125.0%	$4K-95.2%	$83K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	$486K+14.6%	$424K-4.1%	$442K
SG&A Expenses	$657K+23.0%	$534K-74.3%	$2.1M+175.1%	$754K-29.1%	$1.1M-26.4%	$1.4M-12.0%	$1.6M+33.5%	$1.2M
Operating Income	-$657K-23.0%	-$534K+74.3%	-$2.1M-175.1%	-$754K+29.1%	-$1.1M+45.0%	-$1.9M+6.3%	-$2.1M-29.8%	-$1.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$689K-22.4%	-$563K+73.1%	-$2.1M-174.3%	-$763K+28.0%	-$1.1M+46.2%	-$2.0M-482.8%	-$338K+78.7%	-$1.6M
EPS (Diluted)	$-0.65-4.8%	$-0.62+72.9%	$-2.29-175.9%	$-0.83+33.1%	$-1.24+52.7%	$-2.62	$-0.45+78.7%	$-2.11

TTNP Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$2.9M-63.9%	$8.1M+99.3%	$4.1M-49.2%	$8.0M-1.1%	$8.1M-15.1%	$9.5M
Current Assets	$2.9M-63.5%	$8.0M+122.5%	$3.6M-50.2%	$7.2M-1.4%	$7.3M-11.8%	$8.3M
Cash & Equivalents	$2.8M-58.1%	$6.8M+130.2%	$2.9M-51.4%	$6.0M+11.5%	$5.4M+3.6%	$5.2M
Inventory	N/A	$0-100.0%	$106K-63.8%	$293K-10.7%	$328K-41.7%	$563K
Accounts Receivable	N/A	$46K+27.8%	$36K-67.9%	$112K-87.3%	$884K+101.8%	$438K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$483K-66.6%	$1.4M-46.4%	$2.7M-5.6%	$2.9M-37.3%	$4.6M-43.7%	$8.1M
Current Liabilities	$483K-66.6%	$1.4M-45.1%	$2.6M-1.5%	$2.7M-36.8%	$4.2M+17.3%	$3.6M
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$332K-91.7%	$4.0M
Total Equity	$2.4M-63.3%	$6.6M+387.3%	$1.4M-73.5%	$5.1M+45.5%	$3.5M+146.5%	$1.4M
Retained Earnings	-$396.5M-1.2%	-$391.8M-1.4%	-$386.3M-2.7%	-$376.1M-2.4%	-$367.3M-5.2%	-$349.0M

Metric	Q2'25	Q1'25	Q2'24	Q3'24	Q1'24	Q4'23	Q3'23	Q2'23
Total Assets	$3.1M+41.5%	$2.2M-26.2%	$2.9M-18.9%	$3.6M-45.8%	$6.6M-17.8%	$8.1M-19.1%	$10.0M+1131.4%	$812K
Current Assets	$3.1M+41.5%	$2.2M-26.2%	$2.9M-18.9%	$3.6M-45.5%	$6.6M-17.5%	$8.0M-19.0%	$9.9M+1887.8%	$498K
Cash & Equivalents	$2.8M+44.1%	$1.9M-31.3%	$2.8M-16.7%	$3.4M-44.8%	$6.2M-8.9%	$6.8M-16.5%	$8.1M+7610.5%	$105K
Inventory	N/A	N/A	N/A	N/A	N/A	$0	N/A	N/A
Accounts Receivable	N/A	N/A	$38K0.0%	$38K-71.6%	$134K+191.3%	$46K+76.9%	$26K+188.9%	$9K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$263K-5.7%	$279K-42.2%	$483K+30.2%	$371K-33.6%	$559K-61.3%	$1.4M-22.6%	$1.9M+1.1%	$1.8M
Current Liabilities	$263K-5.7%	$279K-42.2%	$483K+30.2%	$371K-33.6%	$559K-61.3%	$1.4M-22.6%	$1.9M+1.1%	$1.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.8M+48.5%	$1.9M-23.1%	$2.4M-24.5%	$3.2M-46.9%	$6.1M-8.4%	$6.6M-18.3%	$8.1M+886.6%	-$1.0M
Retained Earnings	-$397.8M-0.2%	-$397.1M-0.1%	-$396.5M-0.2%	-$395.7M-0.7%	-$392.9M-0.3%	-$391.8M-0.4%	-$390.3M-0.2%	-$389.5M

TTNP Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$3.9M+45.3%	-$7.1M+13.3%	-$8.2M-3.6%	-$7.9M+54.1%	-$17.2M-11.4%	-$15.4M
Capital Expenditures	N/A	$2K	N/A	$23K-95.7%	$540K+110.9%	$256K
Free Cash Flow	N/A	-$7.1M	N/A	-$7.9M+55.4%	-$17.7M-13.0%	-$15.7M
Investing Cash Flow	N/A	$732K	N/A	-$23K+95.7%	-$540K-110.9%	-$256K
Financing Cash Flow	-$62K-100.6%	$10.0M+100.6%	$5.0M-43.6%	$8.8M-50.7%	$17.9M+59.1%	$11.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q2'24	Q3'24	Q1'24	Q4'23	Q3'23	Q2'23
Operating Cash Flow	-$680K+21.6%	-$867K-71.3%	-$506K+27.0%	-$693K-13.1%	-$613K+72.7%	-$2.2M-22.4%	-$1.8M-65.0%	-$1.1M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	$504K	N/A	N/A
Financing Cash Flow	$1.5M+8194.7%	-$19K	N/A	N/A	N/A	$406K	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TTNP Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	87.0%-3.3pp	90.2%-9.8pp	100.0%
Operating Margin	N/A	-3954.9%-2117.4pp	-1837.5%-1224.5pp	-613.0%-461.0pp	-151.9%+150.4pp	-302.3%
Net Margin	N/A	-3026.6%-1194.3pp	-1832.3%-1257.2pp	-575.1%-198.0pp	-377.1%+254.7pp	-631.8%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-161.0%-92.1pp	-68.9%+182.6pp	-251.5%-141.7pp	-109.8%+115.8pp	-225.6%-52.7pp	-172.8%
Current Ratio	6.05+0.5	5.55+4.2	1.37-1.3	2.71+1.0	1.74-0.6	2.31
Debt-to-Equity	0.20-0.0	0.22-1.8	1.98+2.0	0.00-0.1	0.09-2.7	2.80
FCF Margin	N/A	-3855.4%	N/A	-519.1%-152.4pp	-366.7%+236.0pp	-602.7%

Metric	Q2'25	Q1'25	Q2'24	Q3'24	Q1'24	Q4'23	Q3'23	Q2'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	-51525.0%-49611.8pp	-1913.3%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	-8450.0%-6539.2pp	-1910.8%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-22.6%+3.5pp	-26.1%+22.0pp	-48.1%-26.9pp	-21.2%-5.2pp	-16.0%+8.4pp	-24.4%-21.0pp	-3.4%+191.9pp	-195.3%
Current Ratio	11.60+3.9	7.73+1.7	6.05-3.7	9.71-2.1	11.83+6.3	5.55+0.2	5.30+5.0	0.27
Debt-to-Equity	0.09-0.1	0.15-0.0	0.20+0.1	0.11+0.0	0.09-0.1	0.22-0.0	0.23+2.0	-1.79
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

60 degrees pharmaceuticals, Inc. SXTP

$4.5M

Polyrizon Ltd PLRZ

$14.4M

Ensysce Biosciences Inc ENSC

$1.6M

Palisade Bio Inc PALI

$258.1M

Frequently Asked Questions

Is Titan Pharmaceut profitable?

No, Titan Pharmaceut (TTNP) reported a net income of -$4.7M in fiscal year 2024.

What is Titan Pharmaceut's earnings per share (EPS)?

Titan Pharmaceut (TTNP) reported diluted earnings per share of $-5.23 for fiscal year 2024. This represents a 29.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Titan Pharmaceut's EBITDA?

Titan Pharmaceut (TTNP) had EBITDA of -$4.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Titan Pharmaceut's operating cash flow?

Titan Pharmaceut (TTNP) generated -$3.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Titan Pharmaceut's total assets?

Titan Pharmaceut (TTNP) had $2.9M in total assets as of fiscal year 2024, including both current and long-term assets.

How many shares does Titan Pharmaceut have outstanding?

Titan Pharmaceut (TTNP) had 914,234 shares outstanding as of fiscal year 2024.

What is Titan Pharmaceut's current ratio?

Titan Pharmaceut (TTNP) had a current ratio of 6.05 as of fiscal year 2024, which is generally considered healthy.

What is Titan Pharmaceut's debt-to-equity ratio?

Titan Pharmaceut (TTNP) had a debt-to-equity ratio of 0.20 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Titan Pharmaceut's return on assets (ROA)?

Titan Pharmaceut (TTNP) had a return on assets of -161.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Titan Pharmaceut's cash runway?

Based on fiscal year 2024 data, Titan Pharmaceut (TTNP) had $2.8M in cash against an annual operating cash burn of $3.9M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Titan Pharmaceut's Piotroski F-Score?

Titan Pharmaceut (TTNP) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Titan Pharmaceut's earnings high quality?

Titan Pharmaceut (TTNP) has an earnings quality ratio of 0.82x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.